PHS FOI 2025-002263
- Date of request
- 23 October 2025
- Date of response
- 10 November 2025
- FOI request ID
- PHS FOI 2025-002263
- Cancer
- Pharmacy and prescribing
- Population health
Request
I request the following information concerning the cancer medicine pembrolizumab (brand name Keytruda).
- For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide top 10 medicines by total estimated cost for medicines positively appraised, prescribed or issued in all sectors.
- For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide the total expenditure on Pembrolizumab (brand name Keytruda)
- For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide the number of individual patients treated with Pembrolizumab. If it is not possible to provide this information, please explain why.
- For each of the six patients who were/have been on Pembrolizumab for the longest, what has it cost the NHS per patient? If it is not possible to provide this information, please explain why.
- Please provide a list of all licensed indications for which Pembrolizumab is currently used within the NHS. For each indication, please provide the year in which it was first licensed for use. If it is not possible to provide this information, please explain why.
- For each of the past 5 financial years (2019/20 to 2023/24, or the most recent 5-year period available), how many legal challenges or complaints have you had regarding Pembrolizumab and what was the nature of each of these? If it is not possible to provide this information, please explain why.
- For each of the past 10 financial years (2019/20 to 2023/24, or the most recent 10-year period available), how many adverse events, and separately, serious adverse events, have you had which reference Pembrolizumab? If it is not possible to provide this information, please explain why.